The Global Market for Imaging Agents is Projected to Reach US$10.7 Billion by 2022

Emergence of Advanced Imaging Agents and Expanding Indications to Drive the Global Imaging Agents Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Imaging Agents market. The global market for Imaging Agents is projected to reach US$10.7 billion by 2022, driven by aging population, rising healthcare burden compounded by the high prevalence of chronic and infectious diseases, innovation in imaging modalities, and technological advancements in imaging agents.

Imaging agents are pharmaceuticals or biomarkers that aid in enhancing anatomic imaging capabilities of various diagnostic imaging modalities. These agents enable better diagnosis of physiological functions and diseases, as well as improve treatment monitoring. Continuous technological improvements in imaging modalities and advances in imaging agents have led to improved efficacy and safety and expanded use of imaging agents in a wide variety of diagnostic procedures. Growing global population, aging society with rising median age, high incidence and prevalence of various diseases, improving access to healthcare in emerging markets, and a general growth in overall awareness of diseases and benefits of early diagnosis are factors driving growth in the market.

Contrast media represents the largest segment in the global imaging agents market. While the market for contrast media which includes imaging agents for X-ray/CT, MRI and ultrasound modalities is fairly mature, growth is being driven by advances in techniques, emergence of new and safer products, and expansion of applications. Increasing adoption of contrast-enhanced ultrasound (CEUS) diagnostic procedures is a major factor driving demand for contrast media worldwide. A bevy of benefits offered, such as lack of ionizing radiation, low risk of side-effects, possibility of bed-side usage, facilitation of real-time imaging and ability to provide lesion patterns are driving demand for Ultrasound contrast agents in CEUS procedures. In the MRI contrast media market, new agents such as macrocyclic MRI contrast agents are increasing their footprint as old generation gadolinium based agents lose ground due to safety issues. The growth in the market is also driven by growing popularity and adoption of nuclear imaging, driving demand for diagnostic radiopharmaceuticals. Broadening applications and better safety and efficacy benefits are driving adoption of nuclear imaging procedures such as PET and SPECT, which are in turn driving demand for radiopharmaceuticals used in imaging of neurological and cardiac diseases, and cancers. Development and launch of several radiopharmaceuticals are also expected to drive demand in the market.

As stated by the new market research report on Imaging Agents, the United States represents the largest market worldwide supported by the widespread use of molecular imaging for early detection of diseases and improved therapeutic outcomes and attractive reimbursement policies for new and advanced agents. Asia-Pacific ranks as the fastest growing market with a CAGR of 6% through the analysis period led by rising incidence of cancer, cardiac and other diseases, improving income levels, rising awareness, improving access to quality healthcare and increased installation of imaging modalities such as CT, MRI, Nuclear and Ultrasound in hospitals and clinics.

Major players covered in the report include Aytu BioScience, Inc., Bayer Healthcare Pharmaceuticals, Bracco Diagnostics, Inc., Daiichi Sankyo Company Limited, Eisai Co., Ltd., Eli Lilly and Company, GE Healthcare, Guerbet Group, Lantheus Medical Imaging, Inc. and Mallinckrodt plc among others.

The research report titled “Imaging Agents: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for Imaging Agents in value terms for all major geographic markets such as United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, India and Rest of Asia-Pacific), Middle East & Africa and Latin America (Brazil and Rest of Latin America). Product segments analyzed in the report include Contrast Media (X-Ray/CT, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.